{"id":39800,"date":"2025-08-20T20:46:01","date_gmt":"2025-08-20T12:46:01","guid":{"rendered":"https:\/\/flcube.com\/?p=39800"},"modified":"2025-08-20T20:46:02","modified_gmt":"2025-08-20T12:46:02","slug":"chongqing-genrix-bio-pharmaceuticals-gr1802-injection-receives-nmpa-approval-for-seasonal-allergic-rhinitis-in-adolescents","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39800","title":{"rendered":"Chongqing Genrix Bio Pharmaceutical&#8217;s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents"},"content":{"rendered":"\n<p>China-based Chongqing Genrix Biopharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688443:SHA\">SHA: 688443<\/a>) has announced that its investigational product, GR1802 injection, has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of seasonal allergic rhinitis in adolescents. This marks a significant milestone in advancing innovative therapies for adolescent patients suffering from this condition.<\/p>\n\n\n\n<p><strong>GR1802 Injection: A Novel Therapeutic Approach<\/strong><br>GR1802 injection is a recombinant, fully human anti-IL-4R\u03b1 monoclonal antibody independently developed by Chongqing Genrix Bio Pharmaceutical. The product targets IL-4R\u03b1, a key mediator of allergic and inflammatory responses. GR1802 specifically binds to human IL-4R\u03b1 on the cell surface, blocking the binding of IL-4 and IL-13 to IL-4R\u03b1. This inhibition prevents downstream STAT6 phosphorylation and CD23 upregulation, effectively suppressing Th2-type inflammatory responses mediated by IL-4 or IL-13.<\/p>\n\n\n\n<p><strong>Clinical Development Overview<\/strong><br>Prior to this approval for seasonal allergic rhinitis in adolescents, GR1802 injection had already received clinical trial approvals for several other indications. The product is currently in Phase III clinical trials for moderate to severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and allergic rhinitis. Additionally, GR1802 is in a Phase II clinical trial for asthma and a Phase Ib\/II clinical trial for atopic dermatitis in children and adolescents.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/688443_20250820_8XH5.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688443_20250820_8XH5.\"><\/object><a id=\"wp-block-file--media-fb763771-e43d-42ef-9ca8-56f43b3fdaf7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/688443_20250820_8XH5.pdf\">688443_20250820_8XH5<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/688443_20250820_8XH5.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fb763771-e43d-42ef-9ca8-56f43b3fdaf7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802&#8230;<\/p>\n","protected":false},"author":1,"featured_media":39801,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,62,3000,877],"class_list":["post-39800","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-genrix-biopharmaceutical","tag-sha-688443"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Chongqing Genrix Bio Pharmaceutical&#039;s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802 injection, has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of seasonal allergic rhinitis in adolescents. This marks a significant milestone in advancing innovative therapies for adolescent patients suffering from this condition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39800\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chongqing Genrix Bio Pharmaceutical&#039;s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents\" \/>\n<meta property=\"og:description\" content=\"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802 injection, has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of seasonal allergic rhinitis in adolescents. This marks a significant milestone in advancing innovative therapies for adolescent patients suffering from this condition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39800\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T12:46:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-20T12:46:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2002-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39800#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39800\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chongqing Genrix Bio Pharmaceutical&#8217;s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents\",\"datePublished\":\"2025-08-20T12:46:01+00:00\",\"dateModified\":\"2025-08-20T12:46:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39800\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39800#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2002-1.webp\",\"keywords\":[\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"Genrix Biopharmaceutical\",\"SHA: 688443\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39800#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39800\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39800\",\"name\":\"Chongqing Genrix Bio Pharmaceutical's GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39800#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39800#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2002-1.webp\",\"datePublished\":\"2025-08-20T12:46:01+00:00\",\"dateModified\":\"2025-08-20T12:46:02+00:00\",\"description\":\"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802 injection, has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of seasonal allergic rhinitis in adolescents. This marks a significant milestone in advancing innovative therapies for adolescent patients suffering from this condition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39800#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39800\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39800#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2002-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2002-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Chongqing Genrix Bio Pharmaceutical's GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39800#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chongqing Genrix Bio Pharmaceutical&#8217;s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chongqing Genrix Bio Pharmaceutical's GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802 injection, has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of seasonal allergic rhinitis in adolescents. This marks a significant milestone in advancing innovative therapies for adolescent patients suffering from this condition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39800","og_locale":"en_US","og_type":"article","og_title":"Chongqing Genrix Bio Pharmaceutical's GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents","og_description":"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802 injection, has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of seasonal allergic rhinitis in adolescents. This marks a significant milestone in advancing innovative therapies for adolescent patients suffering from this condition.","og_url":"https:\/\/flcube.com\/?p=39800","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-20T12:46:01+00:00","article_modified_time":"2025-08-20T12:46:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2002-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39800#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39800"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chongqing Genrix Bio Pharmaceutical&#8217;s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents","datePublished":"2025-08-20T12:46:01+00:00","dateModified":"2025-08-20T12:46:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39800"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39800#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2002-1.webp","keywords":["Auto-immune","Clinical trial approval \/ initiation","Genrix Biopharmaceutical","SHA: 688443"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39800#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39800","url":"https:\/\/flcube.com\/?p=39800","name":"Chongqing Genrix Bio Pharmaceutical's GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39800#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39800#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2002-1.webp","datePublished":"2025-08-20T12:46:01+00:00","dateModified":"2025-08-20T12:46:02+00:00","description":"China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802 injection, has received clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of seasonal allergic rhinitis in adolescents. This marks a significant milestone in advancing innovative therapies for adolescent patients suffering from this condition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39800#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39800"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39800#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2002-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2002-1.webp","width":1080,"height":608,"caption":"Chongqing Genrix Bio Pharmaceutical's GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39800#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chongqing Genrix Bio Pharmaceutical&#8217;s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2002-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39800"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39800\/revisions"}],"predecessor-version":[{"id":39803,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39800\/revisions\/39803"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39801"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}